Antibody Drug Conjugates / ADCs / 항체-약물 복합체_ALB Technology - 코아사이언스

Antibody Drug Conjugates

	ADCs Linkers	ADCs Cytotoxin

Learn more about ADCs from ADC review: ADC review

Antibody-drug conjugates or ADCs are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of people with cancer. ADCs are complex molecules composed of an antibody (a whole mAb or an antibody fragment such as a single-chain variable fragment [scFv]) linked, via a stable, chemical, linker with labile bonds, to a biological active cytotoxic (anticancer) payload or drug. Antibody Drug Conjugates are examples of bioconjugates and immunoconjugates.Learn more about ADCs from ADC review: ADC review

• Drugs : MMAE, MMAF, DM1, DM4 and etc.
• Linkers: MC-VC-PAB-PNP, Fmoc-VC-PAB-PNP, SMCC, MMC and etc.
• Drug-linkers:DM1-SMCC,MC-VC-PAB-MMAE,SuO-VC-PAB-MMAE,MC-VC-PAB-MMAF and etc.

 

Antibody–drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. So, antibody-drug conjugates allow sensitive discrimination between healthy and diseased tissue. This means that, in contrast to traditional chemotherapeutic agents, antibody-drug conjugates target and attack the cancer cell so that healthy cells are less severely affected.

ADC technology has been an active area of research in recent years, resulting in a number of ADCs in development for various tumor types.The FDA approval of Adcetris® (brentuximab vedotin) in 2011 and Kadcyla® (trastuzumab emtansine or T-DM1) in 2013 has validated the idea of making “armed” antibodies, attracting a lot of attention into this field.

• Adcetris® (brentuximab vedotin) is an antibody-drug conjugate (ADC) directed to the protein CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL).
• Kadcyla (trastuzumab emtansine or T-DM1) Glossary is approved to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.

 

Although the ADC concept is quite simple, successfully designing and developing such a “smart bomb” is a complex task. The design of effective targeting agents has required substantial investigation and modification in the selection of MAbs and their targets, the types of linkers used, and the potency of the toxic agents that are delivered.

코아사이언스 coresciences ALB technology antibody drug conjugates ADCs ADC thechnology cytotoxin cytotoxic anticancer payload bioconjugates immunoconjugates targeted therapy linkers smart bomb 스마트폭탄 의약품 면역 항체 표적 치료제 개발 항암치료제 항체 약물 표적화 기술 세포독성물질 결합 항체 항암효과 화학의약품 small cehmicals 항체의약품 암세포 타깃 항체 항암 항체-약물 접합 항체 신약 항체시밀러 Antibody-Drug Conjugate 기술